High-dose methotrexate with rituximab in patients with primary central nervous system lymphoma

High-dose methotrexate with rituximab in patients with primary central nervous system lymphoma - High-dose methotrexate with rituximab in patients with primary central nervous system lymphoma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012602

Enrollment

Registered

2013-12-17

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary central nervous system lymphoma

Interventions

Arm1:treated with high-dose MTX + Rituximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients were required to have a histologically proven CD20+ B-cell CNS non-Hodgkin lymphoma. Before the start of treatment patients were evaluated by MRI,PET,CT

Exclusion criteria

Exclusion criteria: serum creatinine >1.3mg/dl, creatinine clearance <75ml/minute, white blood cell count <3000 per dL platelet count <100000 per dL positive for hepatitis B surface antigens, hepatitis C seropositivity pregnancy

Design outcomes

Primary

Measure	Time frame
overall survival, progression-free survival, KPS	—

Countries

Japan

Contacts

Public ContactKohei Nakajima

Institute of Health Biosciences,The University of Tokushima Graduate School Neurosurgery

neuros@clin.med.tokushima-u.ac.jp088-633-7149

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026